Previous Close | 0.1610 |
Open | 0.1555 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.1555 - 0.1555 |
52 Week Range | 0.0655 - 0.3262 |
Volume | |
Avg. Volume | 1,775 |
Market Cap | 6.556M |
Beta (5Y Monthly) | 2.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0690 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, BC , April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation announced today the appointment of Kevin Phelps, CPA as Chief Operating Officer. In its current phase of growth and development, AREV Life Sciences Global Corporation appoints Kevin Phelps, CPA and AREV Board Member to the role of Chief Operating Officer. Kevin Phelps brings 40 years of experience in biotec
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announced today its initial research engagement with TransBIOTech. Created in 1999, TransBIOTech is a publicly supported preclinical research organization that works in partnership with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (NSERC) in collaboration with the Canadia
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via InvestorWire - AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announces today completion of its fungi inoculation lab, colonizing and fruiting rooms. The fruiting room has been populated with colonized blocks of Lion's Mane (Hericium erinaceus) containing bioactive substances with beneficial effects on the body, especially the brain, heart and gut. Over the past 3 months, AREV has been building